Sicurezza ed efficacia dei mucolitici in età pediatrica

Translated title of the contribution: Safety and efficacy of mucolytics in paediatric age

Loriana Tartaglia, Francesco Trotta, Paola Baiardi, Ignazio Barbieri, Domenico Del Principe, Pasquale Di Pietro, Paolo Manzoni, Federico Marchetti, Ettore Napoleone, Francesca Rocchi, Paolo Rossi, Rossella Rossi, Carmela Santuccio, Gian Vincenzo Zuccotti

Research output: Contribution to journalArticlepeer-review


Following a signal from France, which showed an increase in the cases of bronchial obstruction and worsening respiratory disorders in children under 2 years of age treated with mucolytics, the Italian Drug Agency (AIFA) has revised the risk/benefit profile of this drug class (ATC R05CB), administrated by oral and rectal route, in children under 2 years of age, authorized at a national level. This re-valuation gave unfavourable results; indeed, despite the widely use of these drugs, mainly available without prescription, and in the absence of sufficient evidence of efficacy in children, the safety profile is compromised by the risk of serious adverse reactions. Therefore, AIFA has adopted a regulatory action, currently under implementation, to contraindicate the medicines, for oral and rectal use, containing acetylcysteine, carbocysteine, ambroxol, bromexine, sobrerol, neltenexine, erdosteine and telmesteine in the age class 0-2 years.

Translated title of the contributionSafety and efficacy of mucolytics in paediatric age
Original languageItalian
Pages (from-to)110-113
Number of pages4
JournalMedico e Bambino
Issue number2
Publication statusPublished - Feb 2011

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Safety and efficacy of mucolytics in paediatric age'. Together they form a unique fingerprint.

Cite this